SOPHiA GENETICS S.A.
SOPHiA GENETICS S.A. (SOPH) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SOPH · as of Sep 30, 2025
Ownership Breakdown
40
Institutional Holders
▲ 8 vs Q2
$84.31M
Total Inst. Value
▲ $33.08M vs Q2
71.67M
Shares Outstanding
freeFloat 72.16%
17.71M
13F Shares Held
▲ 1.19M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SOPH largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GENERATION INVESTMENT MANAGEMENT LLP biological products, (no diagnostic substances) | 6.79M | 10.09% | 10.09% | $32.32B | Nov 10, 2025 | — held |
AKRE CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 3.72M | 5.52% | 5.52% | $17.70B | Nov 13, 2025 | — held |
BANQUE PICTET & CIE SA biological products, (no diagnostic substances) | 2.21M | 3.28% | 3.28% | $10.51B | Oct 21, 2025 | — held |
ALTA WEALTH ADVISORS LLC biological products, (no diagnostic substances) | 1.41M | 2.09% | 2.09% | $6.71B | Nov 3, 2025 | ▲ 1.41M |
PRINCIPAL FINANCIAL GROUP INC biological products, (no diagnostic substances) | 1.39M | 2.07% | 2.07% | $6.62B | Nov 4, 2025 | ▼ 9.0K |
ARCHON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 427.1K | 63.44% | 63.44% | $2.03B | Nov 14, 2025 | ▲ 105.5K |
PICTET & CIE (EUROPE) SA biological products, (no diagnostic substances) | 255.2K | 37.91% | 37.91% | $1.21B | Oct 21, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 225.9K | 33.56% | 33.56% | $1.08B | Nov 14, 2025 | ▼ 358.5K |
FEDERATED HERMES, INC. biological products, (no diagnostic substances) | 210.0K | 31.19% | 31.19% | $999.60M | Nov 3, 2025 | ▼ 10.0K |
EDMOND DE ROTHSCHILD HOLDING S.A. biological products, (no diagnostic substances) | 203.3K | 30.20% | 30.20% | $967.87M | Nov 13, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
13
Increased
+1.60M shares9
New Positions
first time holders8
Decreased
−464.6K shares3
Sold Out
fully exitedNet shares change (top 50)
+1.14M
+1.60M / −464.6K
Net new holders
+11
9 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SOPH insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
28
Buy transactions
68
Sell transactions
0.41
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
CARDOZA GEORGE Chief Financial Officer | Jun 5, 2026 | Purchase | 20,000 | $4.95 | $99.0K | 311.5K | Form 4 ↗ |
Menu Philippe Chief Medical Officer | May 26, 2026 | Sale | 5,000 | $4.95 | $24.8K | 250.8K | Form 4 ↗ |
Muken Ross President | May 19, 2026 | Sale | 761 | $4.60 | $3.5K | 680.9K | Form 4 ↗ |
Xu Zhenyu Chief Scientific Officer | May 19, 2026 | Sale | 608 | $4.60 | $2.8K | 626.3K | Form 4 ↗ |
Camblong Jurgi Chief Executive Officer | May 19, 2026 | Sale | 4,486 | $4.60 | $20.7K | 3.63M | Form 4 ↗ |
Menu Philippe Chief Medical Officer | May 19, 2026 | Sale | 608 | $4.61 | $2.8K | 255.8K | Form 4 ↗ |
Van Well Daan Chief Legal Officer | May 19, 2026 | Sale | 684 | $4.60 | $3.1K | 345.1K | Form 4 ↗ |
Valente Manuela Chief People Officer | May 19, 2026 | Sale | 380 | $4.60 | $1.7K | 214.7K | Form 4 ↗ |
Puylaert Kevin Chief Sales Officer | May 19, 2026 | Sale | 33 | $4.54 | $149.899 | 148.2K | Form 4 ↗ |
Xu Zhenyu Chief Scientific Officer | May 13, 2026 | Sale | 4,000 | $4.54 | $18.2K | 626.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
SOPHiA GENETICS S.A. (SOPH) is primarily owned by institutional investors, who hold approximately 24.7% of total shares outstanding. Company insiders own approximately 27.84%, while retail and public investors account for the remaining 47.45%.
The largest institutional shareholder of SOPHiA GENETICS S.A. is GENERATION INVESTMENT MANAGEMENT LLP, holding approximately 6.79 million shares — equal to 10.09% of outstanding shares — as of September 30, 2025.
A total of 40 institutional investors currently hold SOPH stock, with a combined institutional value of approximately $84,309,953 as of the most recent 13F filing period.
Frequently asked questions
SOPH ownershipSOPHiA GENETICS S.A. (SOPH) is primarily owned by institutional investors, who hold approximately 24.7% of shares. The largest shareholder is GENERATION INVESTMENT MANAGEMENT LLP with a 10.09% stake. Company insiders hold 27.84%. Data sourced from SEC Form 13F as of September 30, 2025.